Ronald Reagan UCLA Medical Center, Los Angeles, CA.
Ronald Reagan UCLA Medical Center, Los Angeles, CA.
Clin Genitourin Cancer. 2021 Jun;19(3):183-193. doi: 10.1016/j.clgc.2020.11.006. Epub 2020 Dec 2.
Metastatic urothelial carcinoma (UC) carries a poor prognosis and a 5-year overall survival of less than 5%, despite standard of care therapy using cisplatin-based chemotherapy and immune checkpoint inhibitors. Thus, novel agents that improve survival and have an acceptable toxicity profile are urgently needed. Antibody-drug conjugates (ADCs) represent a promising new treatment option that utilizes the targeting ability of an antibody to deliver cytotoxic drugs directly to tumors. Many ADCs are currently being investigated for treatment of UC, with enfortumab vedotin being recently approved by the US Food and Drug Administration for treatment of metastatic UC with progressive disease after chemotherapy and/or immune checkpoint inhibitors. Overall, ADCs hold promise as a long-awaited treatment option for UC.
转移性尿路上皮癌（UC）预后不良，即使采用顺铂为基础的化疗和免疫检查点抑制剂的标准治疗方法，其 5 年总生存率仍低于 5%。因此，迫切需要新型药物来提高生存率并具有可接受的毒性特征。抗体药物偶联物（ADC）是一种很有前途的新治疗选择，它利用抗体的靶向能力将细胞毒性药物直接输送到肿瘤部位。目前正在研究许多 ADC 用于治疗 UC，其中 enfortumab vedotin 最近被美国食品和药物管理局批准用于治疗化疗和/或免疫检查点抑制剂治疗后进展性疾病的转移性 UC。总体而言，ADC 有望成为 UC 的一种期待已久的治疗选择。
